11 results on '"BASSET-SEGUIN, Nicole"'
Search Results
2. Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin.
- Author
-
Mascitti, Hélène, De Masson, Adèle, Brunet-Possenti, Florence, Bouaziz, Jean-David, Laly, Pauline, Mourad, Nadim, Garrigues, Jean-Michel, Laurent-Roussel, Sara, Cavelier-Balloy, Bénédicte, Moulonguet, Isabelle, Leschi, Cristina, Mourah, Samia, Bagot, Martine, Lebbé, Céleste, and Basset-Seguin, Nicole
- Published
- 2019
- Full Text
- View/download PDF
3. Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.
- Author
-
Duverger, Lucie, Osio, Amélie, Cribier, Bernard, Mortier, Laurent, De Masson, Adèle, Basset-Seguin, Nicole, Lebbé, Céleste, and Battistella, Maxime
- Subjects
ADNEXAL diseases ,LYMPHOCYTES ,SWEAT glands ,CARCINOMA ,SKIN tumors ,MONOCLONAL antibodies - Abstract
Background: Adnexal carcinomas are rare and heterogeneous skin tumors, for which no standard treatments exist for locally advanced or metastatic tumors. Aim of the study: To evaluate the expression of PD-L1 and CD8 in adnexal carcinomas, and to study the association between PD-L1 expression, intra-tumoral T cell CD8
+ infiltrate, and metastatic evolution. Materials and methods: Eighty-three adnexal carcinomas were included. Immunohistochemistry using anti-PD-L1 monoclonal antibodies (E1L3N and 22C3) and CD8 was performed. PD-L1 expression in tumor and immune cells, and CD8+ tumor-infiltrating lymphocyte (TIL) density were analyzed semi-quantitatively. Results: Among the 60 sweat gland, 18 sebaceous and 5 trichoblastic carcinomas, 11% expressed PD-L1 in ≥ 1% tumor cells, more frequently sweat gland carcinomas (13%, 8/60) including apocrine carcinoma (40%, 2/5) and invasive extramammary Paget disease (57%, 4/7). Immune cells expressed significantly more PD-L1 than tumor cells (p < 0.01). Dense CD8+ TILs were present in 60% trichoblastic, 43% sweat gland, and 39% sebaceous carcinomas. CD8+ TILs were associated with PD-L1 expression by tumor cells (p < 0.01). Thirteen patients out of 47 developed metastases (27%) with a median follow-up of 30.5 months (range 7–36). Expression of PD-L1 by tumor cells was associated with the development of metastasis in univariate analysis (HR 4.0, 95% CI 1.1–15, p = 0.0377) but not in multivariate analysis (HR 4.1, 95% CI 0.6–29, p = 0.15). Conclusion: PD-L1 expression is highly heterogeneous among adnexal carcinoma subtypes, higher in apocrine carcinoma and invasive extramammary Paget disease, and associated with CD8+ TILs. Our data suggest the interest of evaluating anti-PD1 immunotherapy in advanced or metastatic cutaneous adnexal carcinoma. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
4. New Vision in Photoprotection and Photorepair.
- Author
-
Leccia, Marie-Therese, Lebbe, Celeste, Claudel, Jean-Paul, Narda, Mridvika, and Basset-Seguin, Nicole
- Published
- 2019
- Full Text
- View/download PDF
5. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
- Author
-
Gauci, Marie-Léa, Boudou, Philippe, Baroudjian, Barouyr, Vidal-Trecan, Tiphaine, Da Meda, Laetitia, Madelaine-Chambrin, Isabelle, Basset-Seguin, Nicole, Bagot, Martine, Pages, Cécile, Mourah, Samia, Resche-Rigon, Matthieu, Pinel, Sylvine, Sassier, Marion, Rouby, Franck, Eftekhari, Pirayeh, Lebbé, Céleste, and Gautier, Jean-François
- Subjects
THERAPEUTIC use of immunoglobulins ,TREATMENT of diabetes ,MELANOMA treatment ,IMMUNOTHERAPY ,INSULIN resistance ,ADVERSE health care events ,RETROSPECTIVE studies - Abstract
Anti-PD-1 and anti-CTLA-4 antibodies cause immune-related side effects such as autoimmune type 1 diabetes (T1D). It has also been suggested that by increasing TNF-α, IL-2 and IFN-γ production, anti-PD-1 and/or anti-CTLA-4 treatment could affect pancreatic beta cell function and insulin sensitivity. This study was based on a retrospective observational analysis from 2 July 2014 to 27 June 2016, which evaluated the occurrence of T1D and changes in glycemia and C-reactive protein (CRP) plasma concentrations in patients undergoing anti-PD-1 and/or anti-CTLA-4 treatment for melanoma at the Saint Louis Hospital. All cases of T1D that developed during immunotherapy registered in the French Pharmacovigilance Database (FPVD) were also considered. Among the 132 patients included, 3 cases of T1D occurred. For the remaining subjects, blood glucose was not significantly affected by anti-PD-1 treatment, but CRP levels (mg/l) significantly increased during anti-PD-1 treatment (p = 0.017). However, 1 case of type 2 diabetes (T2D) occurred (associated with a longer therapy duration). Moreover, glycemia of patients pretreated (n = 44) or concomitantly treated (n = 8) with anti-CTLA-4 tended to increase during anti-PD-1 therapy (p = 0.068). From the FPVD, we obtained 14 cases of T1D that occurred during immunotherapy and were primarily characterized by the rapidity and severity of onset. In conclusion, in addition to inducing this rare immune-related diabetes condition, anti-PD-1 treatment appears to increase CRP levels, a potential inflammatory trigger of insulin resistance, but without any short-term impact on blood glucose level. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
- Author
-
Gauci, Marie-Léa, Laly, Pauline, Vidal-Trecan, Tiphaine, Baroudjian, Barouyr, Gottlieb, Jérémy, Madjlessi-Ezra, Nika, Meda, Laetitia, Madelaine-Chambrin, Isabelle, Bagot, Martine, Basset-Seguin, Nicole, Pages, Cécile, Mourah, Samia, Boudou, Philippe, Lebbé, Céleste, and Gautier, Jean-François
- Subjects
AUTOIMMUNE diseases ,THYROIDITIS ,PNEUMONIA treatment ,VITILIGO ,INSULIN therapy ,ISLET cell tumor ,THERAPEUTICS - Abstract
Anti-PD-1 antibody treatment is approved in advanced melanoma and provides median overall survival over 24 months. The main treatment-related side effects are immune-related adverse events, which include rash, pruritus, vitiligo, thyroiditis, diarrhoea, hepatitis and pneumonitis. We report a case of autoimmune diabetes related to nivolumab treatment. A 73-year-old man was treated in second line with nivolumab at 3 mg/kg every two weeks for metastatic melanoma. At 6 weeks of treatment, he displayed diabetic ketoacidosis. Nivolumab was withheld 3.5 weeks and insulin therapy was initiated, enabling a normalization of glycaemia and the disappearance of symptoms. Laboratory investigations demonstrated the presence of islet cell autoantibodies, while C-peptide was undetectable. Retrospective explorations on serum banked at week 0 and 3 months before the start of nivolumab, already showed the presence of autoantibodies, but normal insulin, C-peptide secretion and glycaemia. Partial response was obtained at month 3, and nivolumab was then resumed at the same dose. The clinical context and biological investigations before, at and after nivolumab initiation suggest the autoimmune origin of this diabetes, most likely induced by anti-PD-1 antibody in a predisposed patient. The role of PD-1/PD-L1 binding is well known in the pathogenesis of type 1 diabetes. Therefore, this rare side effect can be expected in a context of anti-PD-1 treatment. Glycaemia should be monitored during PD-1/PD-L1 blockade. The presence of autoantibodies before treatment could identify individuals at risk of developing diabetes, but systematic titration may not be relevant considering the rarity of this side effect. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma.
- Author
-
Jannot, Anne-Sophie, Meziani, Roubila, Bertrand, Guylene, Gérard, Benedicte, Descamps, Vincent, Archimbaud, Alain, Picard, Catherine, Ollivaud, Laurence, Basset-Seguin, Nicole, Kerob, Delphine, Lanternier, Guy, Lebbe, Celeste, Saiag, P., Crickx, Beatrice, Clerget-Darpoux, Françoise, Grandchamp, Bernard, and Soufir, Nadem
- Subjects
ALBINOS & albinism ,GENETIC disorders ,SKIN cancer ,MELANOMA ,HUMAN genetics - Abstract
The occuloalbinism 2 (OCA2) gene, localized at 15q11, encodes a melanosomal transmembrane protein that is involved in the most common form of human occulo-cutaneous albinism, a human genetic disorder characterized by fair pigmentation and susceptibility to skin cancer. We wondered whether allele variations at this locus could influence susceptibility to malignant melanoma (MM). In all, 10 intragenic single-nucleotide polymorphisms (SNPs) were genotyped in 113 patients with melanomas and in 105 Caucasian control subjects with no personal or family history of skin cancer. By comparing allelic distribution between cases and controls, we show that MM and OCA2 are associated (p value=0.030 after correction for multiple testing). Then, a recently developed strategy, the ‘combination test’ enabled us to show that a combination formed by two SNPs was most strongly associated to MM, suggesting a possible interaction between intragenic SNPs. In addition, the role of OCA2 on MM risk was also detected using a logistic model taking into account the presence of variants of the melanocortin 1 receptor gene (MC1R, a key pigmentation gene) and all pigmentation characteristics as melanoma risk factors. Our data demonstrate that a second pigmentation gene, in addition to MC1R, is involved in genetic susceptibility to melanoma.European Journal of Human Genetics (2005) 13, 913–920. doi:10.1038/sj.ejhg.5201415; published online 27 April 2005 [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
8. Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development.
- Author
-
Marionnet, Claire, Lalou, Claude, Mollier, Karine, Chazal, Marjorie, Delestaing, Gisele, Compan, Delphine, Verola, Olivier, Vilmer, Catherine, Cuminet, Jerome, Dubertret, Louis, and Basset-Seguin, Nicole
- Subjects
SKIN tumors ,ONCOGENES ,GENE expression ,CANCER genetics ,GENETICS - Abstract
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are skin tumors with different invasive potential. In this work, we analysed mRNA differential expression between seven BCC and five SCC and their normal skin counterparts using 1176 cDNA macroarrays and verification by RT-PCR to identify genes modulated in each tumor type. We identified 37 genes commonly modulated in both tumors and four genes specifically modulated in SCC. Among these latter RhoC and EMMPRIN genes seem to be of particular interest and could participate in SCC aggressivity.Oncogene (2003) 22, 3500-3505. doi:10.1038/sj.onc.1206571 [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
9. P16[supINK4A] is implicated in both the immediate and adaptive response of human keratinocytes to UVB irradiation.
- Author
-
Chazal, Marjorie, Marionnet, Claire, Michel, Laurence, Mollier, Karine, Dazard, Jean-Eudes, Della Valle, Veroniqua, Larsen, Christian-Jacques, Gras, Marie-Pierre, and Basset-Seguin, Nicole
- Subjects
KERATINOCYTES ,GENES ,MESSENGER RNA ,PROTEINS - Abstract
Focuses on a study which examined the expression of the p16[supINK4A-ARF] locus following ultraviolet irradiation of normal human keratinocytes at the messenger RNA and protein levels. Results; Discussion; Materials and methods.
- Published
- 2002
- Full Text
- View/download PDF
10. Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size.
- Author
-
Dazard, Jean-Eudes, Piette, Jacques, Basset-Seguin, Nicole, Blanchard, Jean-Marie, and Gandarillas, Alberto
- Subjects
CELL cycle ,MITOSIS ,KERATINOCYTES - Abstract
p53 transcription factor is mutated in most skin cell carcinomas and in more than 50% of all human malignancies. One of its transcriptional targets is MDM2, which in turn down-regulates p53. The role of the p53/MDM2 regulatory loop upon genotoxic stress is well documented, but less is known about its role in normal tissue homeostasis. We have explored this pathway during the different transitions of the human epidermal differentiation programme and after isolating stem cells, transit amplifying cells or differentiating cells from epidermis. Maximum expression of p53 was found in proliferating keratinocytes. A striking and transient induction of MDM2 and a down-modulation of p53 characterized the transition from proliferation to differentiation in primary human keratinocytes. These changes were delayed in late differentiating carcinoma cells, and were clearly different in suspended primary fibroblasts. Interestingly, these changes correlated with an increase in cell size, at the time of irreversible commitment to differentiation. Induction of MDM2 was also associated with suppression of proliferation in normal, or hyperproliferative, psoriatic epidermis. Moreover, both proteins were induced as keratinocytes were driven to leave the stem cell compartment by c-Myc activation. Overall, our results show a critical regulation of the p53/MDM2 pathway at the epidermal transition from proliferation to differentiation. Oncogene (2000) 19, 3693–3705 [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
11. P16 UV mutations in human skin epithelial tumors.
- Author
-
Soufir, Nadem, Molès, Jean Pierre, Vilmer, Catherine, Moch, Clara, Verola, Olivier, Rivet, Jacqueline, Tesniere, Anne, Dubertret, Louis, and Basset-Seguin, Nicole
- Subjects
MICROBIAL mutation ,SKIN tumors ,EPITHELIAL cells ,MEDICAL genetics - Abstract
The p16 gene expresses two alternative transcripts (p16α and p16β) involved in tumor suppression via the retinoblastoma (Rb) or p53 pathways. Disruption of these pathways can occur through inactivation of p16 or p53, or activating mutations of cyclin dependant kinase 4 gene (Cdk4). We searched for p16, Cdk4 and p53 gene mutations in 20 squamous cell carcinomas (SSCs), 1 actinic keratosis (AK), and 28 basal cell carcinomas (BCCs), using PCR-SSCP. A deletion and methylation analysis of p16 was also performed. Six different mutations (12%) were detected in exon 2 of p16 (common to p16α and p16β), in five out of 21 squamous lesions (24%) (one AK and four SCCs) and one out of 28 BCCs (3.5%). These included four (66%) ultraviolet (UV)-type mutations (two tandems CC : GG to TT : AA transitions and two C : G to T : A transitions at dipyrimidic site) and two transversions. P53 mutations were present in 18 samples (37%), mostly of UV type. Of these, only two (one BCC and one AK) harboured simultaneously mutations of p16, but with no consequence on p16β transcript. Our data demonstrate for the first time the presence of p16 UV induced mutations in non melanoma skin cancer, particularly in the most aggressive SCC type, and support that p16 and p53 are involved in two independent pathways in skin carcinogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.